Добавил:

Sekretar kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.

Вуз:

Ростовский Государственный Медицинский Университет

Предмет:

Медицина общая

Файл:

Книга_3608_Библиотеки_им_академика_М_И_Перельмана

.pdf

Скачиваний:

Добавлен:

29.08.2026

Размер:

83 Мб

Скачать

☆

<<< < Предыдущая 14 15 16 17 18 19 20 21 22 23 24 2526 / 5026 27 28 29 30 31 32 33 34 35 36 37 38 > Следующая >>>

Ranolazine is a piperazine derivative that inhibits fatty acid oxidation, activates pyruvate dehydrogenase, and shifts metabolism toward carbohydrate oxidation, thereby increasing efficiency of oxygen utilization.

173

Ranolazine improves exercise capacity and decreases angina frequency in patients with CAD and was associated with improvement in pain-free walking time (vs. placebo) among patients with intermittent claudication in a single-center pilot study.

174–176

Angiogenic Growth Factors

Angiogenic growth factors have undergone investigation for treatment of PAD. This class of drugs includes VEGF, fibroblast growth factor (FGF), hepatocyte growth factor (HGF), and hypoxia- inducible factor-1α (HIF-1α). They may be administered as recombinant proteins or by gene transfer using plasmid deoxyribonucleic acid (DNA) or an adenoviral vector that encodes the angiogenic growth factor. factor, FGF, and HIF-1α increase collateral blood vessels and improve blood flow in animal models of hindlimb ischemia. Therefore, angiogenic growth factors have the potential to promote collateral blood vessel formation and thereby increase blood flow to the ischemic limbs of patients with PAD.

VASCULAR ENDOTHELIAL GROWTH FACTOR

Several nonrandomized open-label studies found that IA gene transfer therapy of pHVEGF as assessed by MRI or digital subtraction angiography (DSA) in patients with PAD. blood flow and increased ABI in some patients who participated in these trials.

182,183

Also, pHVEGF

182

A randomized placebo-controlled trial of IM VEGF was conducted (DSA) in patients with unilateral intermittent claudication. There was no significant improvement in pain-free or maximal walking distance after 12 or 26 weeks.

FIBROBLAST GROWTH FACTOR

Recombinant FGF2 administered directly into the femoral artery was evaluated in a placebo-controlled study. domized to receive FGF2 on one occasion only, on two occasions 30 days apart, or placebo. One-time administration of FGF2 increased peak walking time at 90 days by 34% compared with 14% for placebo. Yet, there was no significant improvement in peak walking time compared with placebo when FGF2 was administered on two occasions. A nonrandomized study of patients with CLI observed that IM injection of plasmid DNA encoding FGF1 reduced pain and ulcer size and increased the ABI. 2 placebo-controlled study of patients with critical limb ischemia, IM administration of FGF1 using a plasmid vector did not improve ulcer healing, the primary endpoint, but did decrease secondary endpoints including all amputations and the composite of major amputation and death. patients with critical limb IM, FGF1 did not decrease amputationfree survival.

188

187

OTHER ANGIOGENIC GROWTH FACTORS

Hepatocyte growth factor using a plasmid vector and given as an IM injection increased Tc or decrease amputations in a placebo-controlled trial of patients with critical limb ischemia.

Hypoxia-inducible factor-1α is an inducible transcriptional reg-

ulatory factor. In conditions of low oxygen tension, HIF-1α binds to hypoxia-responsive elements in the promoter/enhancer region of target genes, inducing those encoding VEGF-A, platelet-derived growth factor (PDGF), angiotensin-1, and inducible nitric oxide synthase (iNOS).

190–192

In a phase 1 study, 34 patients with CLI with

no revascularization options received an IM injection of an adenovirus encoding HIF-1α. The injections were well tolerated and

177

Vascular endothelial growth

178–181

increased collateral blood vessels,

165

administration improved

165

121

184

185

Patients were ran-

186

In a phase

However, in a follow-up phase 3 study of

but did not improve pain, heal ulcers,

189

associated with complete wound healing in 5 of 18 patients in

193

1 year.

A subsequent trial randomized patients with intermit-

tent claudication to placebo or one of three doses of the adenovirus encoding HIF-1α and found no benefit of HIF-1α on peak walking time, claudication onset time, or ABI up to 1 year after randomization.

194

Stem Cell Therapy

Infusion of endothelial progenitor cells into mice in an experiment model of hindlimb ischemia has been shown to improve blood flow and capillary density in the ischemic hindlimb and reduce the rate of limb loss.

195

Bone marrow mononuclear cells include endothelial progenitor cells. Intramuscular injection of autologous bone marrow–derived mononuclear cells improved collateral blood vessel formation in animal models of myocardial and hindlimb ischemia.

196,197

Consequently, the effect of autologous implantation of bone marrow–derived mononuclear cells was studied in patients with PAD manifested as limb ischemia. Injection of bone marrow mononuclear cells, compared with peripheral blood mononuclear cells, reduced rest pain and improved pain-free walking time. The improvement was sustained for 24 weeks. Angiographic evidence of collateral blood vessel formation was present in many of the patients who received bone marrow–derived mononuclear cells. Additional data supporting potential angiogenic benefit of IM injection or IA infusion of bone marrow–derived mononuclear cells or bone marrow–derived mesenchymal cells for patients with CLI and limited revascularization options have been reported in multiple small single-center early phase trials.

199–204

Many of these studies reported noninvasive testing (e.g., ABI, TBI, plethysmography) rather than angiography to document evidence of angiogenesis.

Several trials are planned or are in progress. The Use of Vascular Repair Cells in Patients with Peripheral Arterial Disease to Treat Critical Limb Ischemia (RESTORE-CLI) trial has randomized 86 patients to stem and progenitor cell therapy with lower-extremity (IM injection) versus a sham control procedure (injection of an electrolyte solution) at 18 U.S. centers.

205

In a published interim analysis, stem cell therapy was associated with improved amputation-free survival, and the results of the completed study are awaited. The Rejuvenating Endothelial Progenitor Cells via Transcutaneous Intraarterial Supplementation (JUVENTAS) trial is another multicenter randomized controlled trial of stem cell therapy in CLI that is currently underway.

206

In JUVENTAS, bone marrow–derived mononuclear cells (vs. placebo) will be administered to the lower extremities through IA infusion, and patients will be followed for the primary endpoint of lower-extremity amputation at 6 months.

Statins

As discussed earlier in this chapter, lipid-lowering therapy with statins reduces the risk of adverse cardiovascular events in patients with atherosclerosis, including those with PAD. Post hoc analysis of the 4S found that simvastatin reduced the risk of new or worsening claudication. therapy improved symptoms of claudication in patients with intermittent claudication. One placebo-controlled trial found that atorvastatin (80 mg/day) for 12 months improved pain-free walking time by 63%, compared with 38% in the placebo group other studies, 6 and 12 months of treatment with simvastatin (40 mg/ day) improved pain-free and maximal walking distance. efficacy of lipid lowering therapy on walking time was not demonstrated, however, in another trial of patients with claudication who were randomized to lovastatin (40 mg) plus niacin 2000 mg daily, lovastatin plus niacin 1000 mg daily, or diet intervention. 28 weeks of follow-up, there was no significant difference in treadmill walking times among the three treatment groups.

There are several potential mechanisms whereby statin ther-

apy may improve symptoms of claudication. These include

Several prospective studies found that statin

207

(Fig. 19-7). In

208,209

210

198

The

After

253

CH 19

MEdiCAl TREATMEnT of PERiPHERAl ARTERy disEAsE

254

10 mg 80 mg Placebo

Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/

125

and refuting these holistic therapies is reviewed here because vascular specialists are frequently queried by their patients about these remedies.

100

Mean change from baseline in PFWT (Sec)

FIGURE 197 Atorvastatin improves pain-free walking time (PFWT) in patients with intermittent claudication. *, P = 0.025 for 80-mg dose at

12 months. (Reproduced with permission from Mohler ER 3 rd, Hiatt WR, Creager MA: Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 108:1481–1486, 2003.)

Baseline

Month 3 Month 6 Month 12

207

reduction in plaque size, improvement in vasomotor regulation of blood flow (particularly in the microcirculation), promotion of angiogenesis, and increased skeletal muscle metabolic function. It is not likely that reduction of plaque size accounts for the improvement in symptoms. This is because angiographic studies have shown that treatment with statins induces only very mild changes in vascular lumen size, and these are unlikely to affect blood flow through a stenotic artery.

211

In the studies that have examined the effect of statins on patients with claudication, there have been no, or only very minor, changes in the ABI. Endothelial function, particularly in the peripheral resistance vessels, is impaired in patients with atherosclerosis, including those with PAD. endothelial function in patients with CAD.

212

Statin therapy has been shown to improve

213,214

Therefore, statin therapy may improve blood flow to the microcirculation and thereby ameliorate symptoms of claudication. Animal studies have found that hypercholesterolemia inhibits angiogenesis. This inhibition may be reduced when cholesterol concentration is reduced by statin therapy, enabling collateral formation to occur. In addition, statins have been shown to increase circulating endothelial progenitor cells independent of cholesterol reduction, and thereby may have a proangiogenic effect. Favorable effects on metabolic function are not likely to account for the observed effects on walking time. Therapy with simvastatin, alone or in combination with ezetimibe, did not improve phosphocreatine recovery time, as assessed by phosphorus-31 magnetic resonance spectroscopy (MRS).

217

Miscellaneous Pharmacological Agents

A number of additional pharmacological agents have been studied as potential therapies for intermittent claudication in recent clinical trials, but unfortunately none has yielded a consistently positive efficacy signal. Multiple serotonin receptor antagonists have been studied with mixed, and largely negative, clinical results

218,219

to date. cant effect on treadmill walking times or quality-of-life parameters compared to placebo.

The antichlamydial antibiotic rifalazil had no signifi-

220

Nutraceuticals and Alternative Therapies

Dietary supplements with nutrients, herbs, and vitamins such as

l-arginine, ginkgo biloba, and vitamin E, as well as ethylenediami-

netetraacetic acid (EDTA), have been studied as complementary therapeutic strategies to improve functional capacity in patients with intermittent claudication. The available evidence supporting

l-ARGININE

∗

Endothelium-derived NO is synthesized from its precursor, larginine, by eNOS. ated by NO, contributes to the physiological regulation of blood flow at rest and during exercise.

221

Endothelium-dependent vasodilation, medi-

222–224

Nitric oxide activates guanylyl cyclase on subjacent vascular smooth muscle and increases cyclic guanosine monophosphate (cGMP) and thereby causes vasodilation. Endothelium-dependent vasodilation is abnormal in conduit and resistance vessels in patients with PAD.

212

In one study, l-arginine administered IV at a dose of 8 g twice daily for 3 weeks improved pain-free walking distance by 230% and maximal walking distance by 155%. ined the effect of a food bar containing B-complex and antioxidant vitamins on walking distance in patients with intermittent claudication.

225

Another study exam-

l-arginine (3.3 g) and

226

Pain-free and maximal walking distance improved by 66% and 23%, respectively, following 2 weeks of therapy in patients eating two bars per day. In a larger placebo-controlled trial, 80 patients with intermittent claudication were randomized to one of four daily or 9 g) administered in thrice-daily divided doses over a 12-week

227

period.

There was less of a beneficial trend of l-arginine ther-

l-arginine doses (0, 3, 6,

apy on maximal walking distance among the patients randomized to the 6-g and 9-g treatment arms. The subsequent Nitric Oxide in Peripheral Arterial Insufficiency (NO-PAIN) randomized 133 claudicants to placebo versus 3 grams daily of oral that was continued for 6 months.

228

The findings of this trial were

l-arginine therapy

dramatic: not only was this a negative study, but randomization

207,209

l-arginine treatment was associated with less brachial artery flow-

mediated vasodilation and less improvement in treadmill walking distance than in the placebo group. In light of these data, long-term

l-arginine supplementation is not recommended for patients with

intermittent claudication.

VITAMIN E

215

Vitamin E (α-tocopherol) is a lipid-soluble antioxidant that has undergone evaluation in patients with intermittent claudication. It inhibits oxidation of polyunsaturated fatty acid. Vitamin E may improve erythrocyte deformability and improve blood flow through the microcirculation because polyunsaturated

216

fatty acids are incorporated into the erythrocyte membrane. A Cochrane systematic review evaluated five placebo-controlled trials of vitamin E in patients with intermittent claudication.

229

The trials, conducted between 1953 and 1975, were small and measured different outcomes, precluding any conclusions regarding the efficacy of vitamin E for intermittent claudication. Both the Heart Protection Study (HPS) and the HOPE study failed to demonstrate any efficacy of vitamin E on adverse cardiovascular events in patients with atherosclerosis, including those with PAD.

27,49

Therefore, vitamin E is not recommended as therapy for patients with PAD, including those with intermittent claudication.

GINKGO BILOBA

Ginkgo biloba is an herb whose major constituents include flavonoids and terpene lactones, such as ginkgolides and bilobalide. Ginkgo may have antioxidant, antiplatelet, and hemorrheological

230

actions.

It is one of the top-selling herbal medicinal products in

the United States.

A meta-analysis of eight randomized placebo-controlled trials found that in recipients of ginkgo, the pain-free claudication distance was 34 meters more than in patients receiving pla-

231

cebo.

In the largest trial, 24 weeks of ginkgo treatment improved

pain-free and maximal walking distance by 45 and 61 meters,

respectively, whereas placebo improved these by 21 and 25 meters, respectively.

232

Doses employed in clinical trials range from 120 to 320 mg/day. The most common dosage is 40 mg 3 times daily. Potential adverse effects of ginkgo include gastrointestinal symptoms, headache, nausea, vomiting, bleeding, or allergic skin reactions.

230

Ginkgo biloba is also associated with adverse interactions with many common prescription medications. It has been associated with cerebral hemorrhage in case

233

reports.

Ginkgo biloba may be considered as an alternative therapy for treatment of claudication, but its efficacy is probably of marginal clinical importance.

DISODIUM ETHYLENEDIAMINETETRAACETIC ACID (EDTA)

EDTA combines with polyvalent cations, including calcium ions, to form a soluble nonionic complex that can be excreted. It requires IV administration and is usually administered two or more times a week. The rationale for using EDTA in patients with atherosclerosis, including those with PAD, is to leech calcium out of atherosclerotic plaque, induce plaque regression, and reduce the severity of stenosis. Also, EDTA may decrease metal ion- dependent formation of reactive oxygen species (ROS) and metal ion-dependent lipid peroxidation. port its efficacy in atherosclerosis.

234

There is limited biological evidence to sup-

235

The Program to Assess Alternative Treatment Strategies to Achieve Health (PATCH) assessed the effect of EDTA on endotheliumdependent vasodilation in patients with CAD. Up to 33 treatments of IV EDTA over a 6-month period caused no changes in peripheral endothelial function. EDTA on the severity of atherosclerosis in patients with PAD.

236

One clinical trial found no effect of

237

Two systematic reviews evaluated four placebo-controlled trials that assessed the efficacy of EDTA in patients with intermittent claudi-

238,239

cation.

These reviews found no evidence that EDTA improves pain-free or maximal walking distance in patients with intermittent claudication.

Potential serious adverse effects of EDTA include hypocalcemia, renal insufficiency, and proteinuria. Additional side effects include gastrointestinal and musculoskeletal symptoms, hypertension, tachycardia, and fever. Based on lack of efficacy as well as safety concerns, EDTA should not be used to treat patients with intermittent claudication.

Conclusions

Patients with PAD are at increased risk for adverse cardiovascular events such as MI, stroke, and death and have impaired functional capacity and qualify of life. In severe circumstances, limb viability is threatened. Comprehensive care of the PAD patient must address all aspects of care: prevention of cardiovascular events, foot care, and therapies to improve leg symptoms. Risk factor modification and antiplatelet therapy are critical components of the management of all patients with PAD. Supervised exercise rehabilitation and the PDE inhibitor cilostazol improve walking distance in patients with claudication. Unfortunately, the pharmacological armamentarium for treatment of claudication is limited. Available medical therapies are not effective in preserving limb viability for patients with critical limb ischemia, so these patients should be considered for revascularization, as reviewed in the next two chapters. Promising new therapies for claudication and critical limb ischemia, particularly stem cell therapy, are undergoing extensive clinical investigation.

REFERENCES

1. Hirsch AT, Haskal ZJ, Hertzer NR, et al: ACC/AHA 2005 practice guidelines for the

management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to

Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic InterSociety Consensus; and Vascular Disease Foundation, Circulation 113:e463–e654, 2006.

2. Rooke TW, Hirsch AT, Misra S, et al: 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, Circulation 124:2020–2045, 2011.

3. Gardner AW: The effect of cigarette smoking on exercise capacity in patients with intermittent claudication, Vasc Med 1:181–186, 1996.

4. Quick CR, Cotton LT: The measured effect of stopping smoking on intermittent claudication, Br J Surg 69(Suppl):S24–S26, 1982.

5. Jonason T, Bergstrom R: Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality, Acta Med Scand 221:253–260, 1987.

6. Powell JT, Greenhalgh RM: Changing the smoking habit and its influence on the management of vascular disease, Acta Chir Scand Suppl 555:99–103, 1990.

7. Faulkner KW, House AK, Castleden WM: The effect of cessation of smoking on the accumulative survival rates of patients with symptomatic peripheral vascular disease, Med J Aust 1:217–219, 1983.

8. Lassila R, Lepantalo M: Cigarette smoking and the outcome after lower limb arterial surgery, Acta Chir Scand 154:635–640, 1988.

9. Law M, Tang JL: An analysis of the effectiveness of interventions intended to help people stop smoking, Arch Intern Med 155:1933–1941, 1995.

10. Hennrikus D, Joseph AM, Lando HA, et al: Effectiveness of a smoking cessation program for peripheral artery disease patients: a randomized controlled trial, J Am Coll Cardiol 56:2105–2112, 2010.

11. Jorenby DE, Leischow SJ, Nides MA, et al: A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation, N Engl J Med 340:685–691, 1999.

12. Jorenby DE, Hays JT, Rigotti NA, et al: Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs. placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial, JAMA 296:56–63, 2006.

13. Rigotti NA, Pipe AL, Benowitz NL, et al: Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial, Circulation 121:221–229, 2011.

14. Varenicline package insert, 2011Pfizer, Inc.

15. Bupropion (Zyban) package insert, 2011GlaxoSmithKline.

16. Bowlin SJ, Medalie JH, Flocke SA, et al: Epidemiology of intermittent claudication in middle-aged men, Am J Epidemiol 140:418–430, 1994.

17. Newman AB, Siscovick DS, Manolio TA, et al: Ank le-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group, Circulation 88:837–845, 1993.

18. Murabito JM, D'Agostino RB, Silbershatz H, et al: Intermittent claudication. A risk profile from the Framingham Heart Study, Circulation 96:44–49, 1997.

19. Fowkes FG, Housley E, Riemersma RA, et al: Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study, Am J Epidemiol 135:331–340, 1992.

20. Mowat BF, Skinner ER, Wilson HM, et al: Alterations in plasma lipids, lipoproteins and high density lipoprotein subfractions in peripheral arterial disease, Atherosclerosis 131: 161–166, 1997.

21. Rubins HB, Robins SJ, Collins D, et al: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group, N Engl J Med 341:410–418, 1999.

22. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S), Lancet 344:1383–1389, 1994.

23. Sacks FM, Pfeffer MA, Moye LA, et al: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators, N Engl J Med 335:1001–1009, 1996.

24. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group, N Engl J Med 339:1349–1357, 1998.

25. Hirsch AT, Criqui MH, Treat-Jacobson D, et al: Peripheral arterial disease detection, awareness, and treatment in primary care, JAMA 286:1317–1324, 2001.

26. Zheng ZJ, Sharrett AR, Chambless LE, et al: Associations of ankle-brachial index with clinical coronary heart disease, stroke and preclinical carotid and popliteal atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) Study, Atherosclerosis 131:115–125, 1997.

27. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial, Lancet 360:7–22, 2002.

28. Pedersen TR, Kjekshus J, Pyorala K, et al: Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S), Am J Cardiol 81:333–335,

1998.

29. MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience, Eur Heart J 20:725–741, 1999.

30. Heart Protection Study Collaborative Group: Randomized trial of the effects of cholesterollowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions, J Vasc Surg 45:645–654, 2007 discussion 653–644.

31. Goldbourt U, Yaari S, Medalie JH: Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men, Arterioscler Thromb Vasc Biol 17:107–113, 1997.

32. Gordon DJ, Rifkind BM: High-density lipoprotein–the clinical implications of recent studies, N Engl J Med 321:1311–1316, 1989.

33. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study, Circulation 102:21–27, 2000.

255

CH 19

MEdiCAl TREATMEnT of PERiPHERAl ARTERy disEAsE

256

Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/

34. Keech A, Simes RJ, Bar ter P, et al: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial, Lancet 366:1849–1861, 2005.

35. Psaty BM, Lumley T, Furberg CD, et al: Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis, JAMA 289:2534–2544, 2003.

36. Major outcomes in high-risk hypertensive patients randomized to angiotensin-

converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), JAMA 288: 2981–2997, 2002.

37. Lip GY, Makin AJ: Treatment of hypertension in peripheral arterial disease, Cochrane Database Syst Rev 2003 CD003075.

38. Frishman WH: Beta-adrenergic receptor blockers. Adverse effects and drug interactions, Hypertension 11:II21–II29, 1988.

39. Rodger JC, Sheldon CD, Lerski RA, et al: Intermittent claudication complicating betablockade, BMJ 1:1125, 1976.

40. Roberts DH, Tsao Y, McLoughlin GA, et al: Placebo-controlled comparison of captopril, atenolol, labetalol, and pindolol in hypertension complicated by intermittent claudication, Lancet 2:650–653, 1987.

41. Solomon SA, Ramsay LE, Yeo WW, et al: Beta blockade and intermittent claudication: placebo controlled trial of atenolol and nifedipine and their combination, BMJ 303: 1100–1104, 1991.

42. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction, N Engl J Med 304:801–807, 1981.

43. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results, JAMA 247:1707–1714, 1982.

44. Mangano DT, Layug EL, Wallace A, et al: Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group, N Engl J Med 335:1713–1720, 1996.

45. Poldermans D, Boersma E, Bax JJ, et al: The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group, N Engl J Med 341:1789–1794, 1999.

46. Radack K, Deck C: Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials, Arch Intern Med 151:1769–1776, 1991.

47. Espinola-K lein C, Weisser G, Jagodzinski A, et al: Beta-blockers in patients with intermittent claudication and arterial hypertension: results from the nebivolol or metoprolol in arterial occlusive disease trial, Hypertension 58:148–154, 2011.

48. Diehm C, Pittrow D, Lawall H: Effect of nebivolol vs. hydrochlorothiazide on the walking capacity in hypertensive patients with intermittent claudication, J Hypertens 29: 1448–1456, 2011.

49. Yusuf S, Sleight P, Pogue J, et al: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators, N Engl J Med 342:145–153, 2000.

50. Overlack A, Adamczak M, Bachmann W, et al: ACE-inhibition with perindopril in essential hypertensive patients with concomitant diseases. The Perindopril Therapeutic Safety Collaborative Research Group, Am J Med 97:126–134, 1994.

51. Ahimastos AA, Lawler A, Reid CM, et al: Brief communication: ramipril markedly improves walking ability in patients with peripheral arterial disease: a randomized trial, Ann Intern Med 144:660–664, 2006.

52. Estacio RO, Jeffers BW, Hiatt WR, et al: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension, N Engl J Med 338:645–652, 1998.

53. Mehler PS, Coll JR, Estacio R, et al: Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes, Circulation 107:753–756, 2003.

54. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE Study Investigators, Can J Cardiol 12:127–137, 1996.

55. Yusuf S, Teo KK, Pogue J, et al: Telmisartan, ramipril, or both in patients at high risk for vascular events, N Engl J Med 358:1547–1559, 2008.

56. Adler AI, Stevens RJ, Neil A, et al: UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes, Diabetes Care 25:894–899, 2002.

57. Meijer W T, Hoes AW, Rutgers D, et al: Peripheral arterial disease in the elderly: the Rotterdam Study, Arterioscler Thromb Vasc Biol 18:185–192, 1998.

58. Jude EB, Oyibo SO, Chalmers N, et al: Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome, Diabetes Care 24:1433–1437, 2001.

59. Bowers BL, Valentine RJ, Myers SI, et al: The natural history of patients with claudication with toe pressures of 40 mmHg or less, J Vasc Surg 18:506–511, 1993.

60. Resnick HE, Carter EA, Sosenko JM, et al: Incidence of lower-extremity amputation in American Indians: the Strong Heart Study, Diabetes Care 27:1885–1891, 2004.

61. Tahrani AA, Bailey CJ, Del Prato S, et al: Management of type 2 diabetes: new and future developments in treatment, Lancet 378:182–197, 2011.

62. Dluhy RG, McMahon GT: Intensive glycemic control in the ACCORD and ADVANCE trials, N Engl J Med 358:2630–2633, 2008.

63. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group, N Engl J Med 329:977–986, 1993.

64. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial, Am J Cardiol 75:894–903, 1995.

65. Nathan DM, Cleary PA, Backlund JY, et al: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes, N Engl J Med 353:2643–2653, 2005.

66. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS

33). UK Prospective Diabetes Study (UKPDS) Group, Lancet 352:837–853, 1998.

67. Knatterud GL, Klimt CR, Levin ME, et al: Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VII. Mortality and selected nonfatal events with insulin treatment, JAMA 240:37–42, 1978.

68. Holman RR, Paul SK, Bethel MA, et al: 10-year follow-up of intensive glucose control in type 2 diabetes, N Engl J Med 359:1577–1589, 2008.

69. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group, Lancet 352:854–865, 1998.

70. Dormandy JA, Charbonnel B, Eckland DJ, et al: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial, Lancet 366:1279–1289,

2005.

71. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes, N Engl J Med 356:2457–2471, 2007.

72. Home PD, Pocock SJ, Beck-Nielsen H, et al: Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial, Lancet 373:2125–2135, 2009.

73. Rosiglitazone maleate package insert, 2011.

74. Gerstein HC, Miller ME, Byington RP, et al: Effects of intensive glucose lowering in type 2 diabetes, N Engl J Med 358:2545–2559, 2008.

75. Duckworth W, Abraira C, Moritz T, et al: Glucose control and vascular complications in veterans with type 2 diabetes, N Engl J Med 360:129–139, 2009.

76. Patel A, MacMahon S, Chalmers J, et al: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes, N Engl J Med 358:2560–2572, 2008.

77. Peripheral arterial disease in people with diabetes, Diabetes Care 26:3333–3341, 2003.

78. Standards of medical care for patients with diabetes mellitus, Diabetes Care (Suppl 1):S33– S50, 2003.

79. Skyler JS, Bergenstal R, Bonow RO, et al: Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association, J Am Coll Cardiol 53:298–304, 2009.

80. Welch GN, Loscalzo J: Homocysteine and atherothrombosis, N Engl J Med 338:1042–1050,

1998.

81. van den Bosch MA, Bloemenkamp DG, Mali WP, et al: Hyperhomocysteinemia and risk for peripheral arterial occlusive disease in young women, J Vasc Surg 38:772–778, 2003.

82. Malinow MR, Kang SS, Taylor LM, et al: Prevalence of hyperhomocysteinemia in patients with peripheral arterial occlusive disease, Circulation 79:1180–1188, 1989.

83. Darius H, Pittrow D, Haberl R, et al: Are elevated homocysteine plasma levels related to peripheral arterial disease? Results from a cross-sectional study of 6880 primary care patients, Eur J Clin Invest 33:751–757, 2003.

84. Taylor LM Jr, DeFrang RD, Harris EJ Jr, et al: The association of elevated plasma homocysteine with progression of symptomatic peripheral arterial disease, J Vasc Surg 13:128–136, 1991.

85. den Heijer M, Koster T, Blom HJ, et al: Hyperhomocysteinemia as a risk factor for deep-vein thrombosis, N Engl J Med 334:759–762, 1996.

86. Vermeulen EG, Stehouwer CD, Twisk JW, et al: Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial, Lancet 355:517–522, 2000.

87. Lonn E, Yusuf S, Arnold MJ, et al: Homocysteine lowering with folic acid and B vitamins in vascular disease, N Engl J Med 354:1567–1577, 2006.

88. Lonn E, Held C, Arnold JM, et al: Rationale, design and baseline characteristics of a large, simple, randomized trial of combined folic acid and vitamins B6 and B12 in high-risk patients: the Heart Outcomes Prevention Evaluation (HOPE)-2 trial, Can J Cardiol 22: 47–53, 2006.

89. Bonaa KH, Njolstad I, Ueland PM, et al: Homocysteine lowering and cardiovascular events after acute myocardial infarction, N Engl J Med 354:1578–1588, 2006.

90. Armitage JM, Bowman L, Clarke RJ, et al: Effects of homocysteine-lowering with folic acid plus vitamin B12 vs. placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial, JAMA 303:2486–2494, 2010.

91. Antithrombotic Trialists Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients, BMJ 324:71, 2002.

92. Collaborative overview of randomised trials of antiplatelet therapy–I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration, BMJ 308:81–106, 1994.

93. Baigent C, Blackwell L, Collins R, et al: Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials, Lancet 373:1849–1860, 2009.

94. Collaborative overview of randomised trials of antiplatelet therapy–II: maintenance of vascular graft or arterial patency by antiplatelet therapy. Antiplatelet Trialists' Collaboration, BMJ 308:159–168, 1994.

95. Balsano F, Violi F: Effect of picotamide on the clinical progression of peripheral vascular disease. A double-blind placebo-controlled study. The ADEP Group, Circulation 87:1563– 1569, 1993.

96. Berger JS, Krantz MJ, Kittelson JM, et al: Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials, JAMA 301:1909–1919, 2009.

97. Catalano M, Born G, Peto R: Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial, J Intern Med 261:276–284, 2007.

98. Belch J, MacCuish A, Campbell I, et al: The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease, BMJ 337:a1840, 2008.

99. Fowkes FG, Price JF, Stewart MC, et al: Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial, JAMA 303:841–848, 2010.

100. Drugs for the heart, ed 5, Philadelphia, 2001, WB Saunders.

101. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee, Lancet 348:1329–1339, 1996.

102. Yusuf S, Zhao F, Mehta SR, et al: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation, N Engl J Med 345:494–502, 2001.

103. Bhatt DL, Fox KA, Hacke W, et al: Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events, N Engl J Med 354:1706–1717, 2006.

104. Cacoub PP, Bhatt DL, Steg PG, et al: Patients with peripheral arterial disease in the CHARISMA trial, Eur Heart J 30:192–201, 2009.

105. Belch JJ, Dormandy J, Biasi GM, et al: Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial, J Vasc Surg 52:825–833, 833 e821–833 e822, 2010.

106. Cosmi B, Conti E, Coccheri S: Anticoagulants (heparin, low molecular weight heparin and oral anticoagulants) for intermittent claudication, Cochrane Database Syst Rev 2001 CD001999.

107. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (the Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomised trial, Lancet 355:346–351, 2000.

108. Anand S, Yusuf S, Xie C, et al: Oral anticoagulant and antiplatelet therapy and peripheral arterial disease, N Engl J Med 357:217–227, 2007.

109. Sobel M, Verhaeghe R: Antithrombotic therapy for peripheral artery occlusive disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition), Chest 133:815S–843S, 2008.

110. O'Brien-Irr MS, Harris LM, Dosluoglu HH, et al: Endovascular intervention for treatment of claudication: is it cost-effective? Ann Vasc Surg 24:833–840, 2010.

111. Treesak C, Kasemsup V, Treat-Jacobson D, et al: Cost-effectiveness of exercise training to improve claudication symptoms in patients with peripheral arterial disease, Vasc Med 9:279–285, 2004.

112. Gardner AW, Poehlman ET: Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis, JAMA 274:975–980, 1995.

113. Leng GC, Fowler B, Ernst E: Exercise for intermittent claudication, Cochrane Database Syst Rev 2000 CD000990.

114. McDermott MM, Ades P, Guralnik JM, et al: Treadmill exercise and resistance training in patients with peripheral arterial disease with and without intermittent claudication: a randomized controlled trial, JAMA 301:165–174, 2009.

115. Murphy TP, Cutlip DE, Regensteiner JG, et al: CLEVER Study Investigators: Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease: six-month outcomes from the claudication: exercise versus endoluminal revascularization (CLEVER) study, Circulation 125:130–139, 2012.

116. Regensteiner JG, Meyer TJ, Krupski WC, et al: Hospital vs. home-based exercise rehabilitation for patients with peripheral arterial occlusive disease, Angiology 48:291–300, 1997.

117. Degischer S, Labs KH, Hochstrasser J, et al: Physical training for intermittent claudication: a comparison of structured rehabilitation versus home-based training, Vasc Med 7:109–115,

2002.

118. Gardner AW, Parker DE, Montgomery PS, et al: Efficacy of quantified home-based exercise and supervised exercise in patients with intermittent claudication: a randomized controlled trial, Circulation 123:491–498, 2011.

119. Stewart KJ, Hiatt WR, Regensteiner JG, et al: Exercise training for claudication, N Engl J Med 347:1941–1951, 2002.

120. Duscha BD, Robbins JL, Jones WS, et al: Angiogenesis in skeletal muscle precede improvements in peak oxygen uptake in peripheral artery disease patients, Arterioscler Thromb Vasc Biol 31:2742–2748, 2011.

121. Lloyd PG, Yang HT, Terjung RL: Arteriogenesis and angiogenesis in rat ischemic hindlimb: role of nitric oxide, Am J Physiol Heart Circ Physiol 281:H2528–H2538, 2001.

122. Mathien GM, Terjung RL: Muscle blood flow in trained rats with peripheral arterial insufficiency, Am J Physiol 258:H759–H765, 1990.

123. Laufs U, Werner N, Link A, et al: Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis, Circulation 109:220–226, 2004.

124. Prior BM, Yang HT, Terjung RL: What makes vessels grow with exercise training? J Appl Physiol 97:1119–1128, 2004.

125. Niebauer J, Maxwell AJ, Lin PS, et al: Impaired aerobic capacity in hypercholesterolemic mice: partial reversal by exercise training, Am J Physiol 276:H1346–H1354, 1999.

126. Buckwalter JB, Curtis VC, Valic Z, et al: Endogenous vascular remodeling in ischemic skeletal muscle: a role for nitric oxide, J Appl Physiol 94:935–940, 2003.

127. Gardner AW, Katzel LI, Sorkin JD, et al: Exercise rehabilitation improves functional outcomes and peripheral circulation in patients with intermittent claudication: a randomized controlled trial, J Am Geriatr Soc 49:755–762, 2001.

128. Hiatt WR, Regensteiner JG, Hargarten ME, et al: Benefit of exercise conditioning for patients with peripheral arterial disease, Circulation 81:602–609, 1990.

129. Gokce N, Vita JA, Bader DS, et al: Effect of exercise on upper and lower extremity endothelial function in patients with coronary artery disease, Am J Cardiol 90:124–127, 2002.

130. Brendle DC, Joseph LJ, Corretti MC, et al: Effects of exercise rehabilitation on endothelial reactivity in older patients with peripheral arterial disease, Am J Cardiol 87:324–329, 2001.

131. Brass EP: Skeletal muscle metabolism as a target for drug therapy in peripheral arterial disease, Vasc Med 1:55–59, 1996.

132. Hiatt WR, Regensteiner JG, Wolfel EE, et al: Effect of exercise training on skeletal muscle histology and metabolism in peripheral arterial disease, J Appl Physiol 81:780–788, 1996.

133. Gardner AW, Forrester L, Smith GV: Altered gait profile in subjects with peripheral arterial disease, Vasc Med 6:31–34, 2001.

134. Collins TC, Lunos S, Carlson T, et al: Effects of a home-based walking intervention on mobility and quality of life in people with diabetes and peripheral arterial disease: a randomized, controlled trial, Diabetes Care 34:2174–2179, 2011.

135. Villemur B, Marquer A, Gailledrat E, et al: New rehabilitation program for intermittent claudication: interval training with active recovery. Pilot study, Ann Phys Rehabil Med 54:275–281, 2011.

136. Bronas UG, Treat-Jacobson D, Leon AS: Comparison of the effect of upper body-ergometry aerobic training vs. treadmill training on central cardiorespiratory improvement and walking distance in patients with claudication, J Vasc Surg 53:1557–1564, 2011.

137. Saxton JM, Zwierska I, Blagojevic M, et al: Upper- versus lower-limb aerobic exercise training on health-related quality of life in patients with symptomatic peripheral arterial disease, J Vasc Surg 53:1265–1273, 2011.

138. Oida K, Ebata K, Kanehara H, et al: Effect of cilostazol on impaired vasodilatory response of the brachial artery to ischemia in smokers, J Atheroscler Thromb 10:93–98, 2003.

139. Tanaka T, Ishikawa T, Hagiwara M, et al: Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle, Pharmacology 36:313–320, 1988.

140. Woo SK, Kang WK, Kwon KI: Pharmacokinetic and pharmacodynamic modeling of the antiplatelet and cardiovascular effects of cilostazol in healthy humans, Clin Pharmacol Ther 71:246–252, 2002.

141. Igawa T, Tani T, Chijiwa T, et al: Potentiation of anti-platelet aggregating activity of cilostazol with vascular endothelial cells, Thromb Res 57:617–623, 1990.

142. Pande RL, Hiatt WR, Zhang P, et al: A pooled analysis of the durability and predictors of treatment response of cilostazol in patients with intermittent claudication, Vasc Med 15:181–188, 2010.

143. Soga Y, Iida O, Hirano K, et al: Impact of cilostazol after endovascular treatment for infrainguinal disease in patients with critical limb ischemia, J Vasc Surg 54:1659–1667, 2011.

144. Miyashita Y, Saito S, Miyamoto A, et al: Cilostazol increases skin perfusion pressure in severely ischemic limbs, Angiology 62:15–17, 2011.

145. Cilostazol package insert, 2011.

146. Dawson DL, Cutler BS, Hiatt WR, et al: A comparison of cilostazol and pentoxifylline for treating intermittent claudication, Am J Med 109:523–530, 2000.

147. Cohn JN, Goldstein SO, Greenberg BH, et al: A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators, N Engl J Med 339:1810–1816, 1998.

148. Packer M, Carver JR, Rodeheffer RJ, et al: Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group, N Engl J Med 325:1468–1475,

1991.

149. Hiatt WR, Money SR, Brass EP: Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects), J Vasc Surg 47:330–336, 2008.

150. Reiter M, Bucek RA, Stumpflen A, et al: Prostanoids for intermittent claudication, Cochrane Database Syst Rev 2004 CD000986.

151. Mohler ER 3rd, Hiatt WR, Olin JW, et al: Treatment of intermittent claudication with beraprost sodium, an orally active prostaglandin I2 analogue: a double-blinded, randomized, controlled trial, J Am Coll Cardiol 41:1679–1686, 2003.

152. Lievre M, Morand S, Besse B, et al: Oral beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group, Circulation 102:426–431, 2000.

153. Creager MA, Pande RL, Hiatt WR: A randomized trial of iloprost in patients with intermittent claudication, Vasc Med 13:5–13, 2008.

154. Second European Consensus Document on chronic critical leg ischemia, Circulation 84:IV1–IV26, 1991.

155. Prostanoids for chronic critical leg ischemia. A randomized, controlled, open-label trial with prostaglandin E1. The ICAI Study Group. Ischemia Cronica degli Arti Inferiori, Ann Intern Med 130:412–421, 1999.

156. Two randomised and placebo-controlled studies of an oral prostacyclin analogue (iloprost) in severe leg ischaemia. The Oral Iloprost in severe Leg Ischaemia Study Group, Eur J Vasc Endovasc Surg 20:358–362, 2000.

157. Belch JJ, Ray S, Rajput-Ray M, et al: The Scottish-Finnish-Swedish PARTNER study of taprostene versus placebo treatment in patients with critical limb ischemia, Int Angiol 30:150–155, 2011.

158. Lewis P, Psaila JV, Davies WT, et al: Nifedipine in patients with peripheral vascular disease, Eur J Vasc Surg 3:159–164, 1989.

159. Bagger JP, Helligsoe P, Randsbaek F, et al: Effect of verapamil in intermittent claudication A randomized, double-blind, placebo-controlled, cross-over study after individual doseresponse assessment, Circulation 95:411–414, 1997.

160. Dawson DL, Zheng Q, Worthy SA, et al: Failure of pentoxifylline or cilostazol to improve blood and plasma viscosity, fibrinogen, and erythrocyte deformability in claudication, Angiology 53:509–520, 2002.

161. Schratzberger P, Dunzendorfer S, Reinisch N, et al: Mediator-dependent effects of pentoxifylline on endothelium for transmigration of neutrophils, Immunopharmacology 41:65–75, 1999.

162. Rao KM, Simel DL, Cohen HJ, et al: Effects of pentoxifylline administration on blood viscosity and leukocyte cytoskeletal function in patients with intermittent claudication, J Lab Clin Med 115:738–744, 1990.

163. Hood SC, Moher D, Barber GG: Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials, CMAJ 155:1053–1059, 1996.

164. Girolami B, Bernardi E, Prins MH, et al: Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis, Arch Intern Med 159:337–345, 1999.

165. Intravenous pentoxifylline for the treatment of chronic critical limb ischaemia. The European Study Group, Eur J Vasc Endovasc Surg 9:426–436, 1995.

166. Efficacy and clinical tolerance of parenteral pentoxifylline in the treatment of critical lower limb ischemia. A placebo controlled multicenter study. Norwegian Pentoxifylline Multicenter Trial Group, Int Angiol 15:75–80, 1996.

167. Broderick TL, Quinney HA, Lopaschuk GD: Carnitine stimulation of glucose oxidation in the fatty acid perfused isolated working rat heart, J Biol Chem 267:3758–3763, 1992.

168. Hiatt WR, Regensteiner JG, Creager MA, et al: Propionyl-l-carnitine improves exercise performance and functional status in patients with claudication, Am J Med 110:616–622, 2001.

169. Brevetti G, Diehm C, Lambert D: European multicenter study on propionyl-l-carnitine in intermittent claudication, J Am Coll Cardiol 34:1618–1624, 1999.

170. Brevetti G, Perna S, Sabba C, et al: Propionyl-l-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study, J Am Coll Cardiol 26:1411–1416, 1995.

171. Brevetti G, Perna S, Sabba C, et al: Effect of propionyl-l-carnitine on quality of life in intermittent claudication, Am J Cardiol 79:777–780, 1997.

257

CH 19

MEdiCAl TREATMEnT of PERiPHERAl ARTERy disEAsE

258

Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/

172. Hiatt WR, Creager MA, Amato A, et al: Effect of propionyl-l-carnitine on a background of monitored exercise in patients with claudication secondary to peripheral artery disease, J Cardiopulm Rehabil Prev 31:125–132, 2011.

173. Stanley WC: Myocardial energy metabolism during ischemia and the mechanisms of metabolic therapies, J Cardiovasc Pharmacol Ther 9(Suppl 1):S31–S45, 2004.

174. Ma A, Garland WT, Smith WB, et al: A pilot study of ranolazine in patients with intermittent claudication, Int Angiol 25:361–369, 2006.

175. Chaitman BR, Skettino SL, Parker JO: v: Anti-ischemic effects and long-term survival

during ranolazine monotherapy in patients with chronic severe angina, J Am Coll Cardiol 43:1375–1382, 2004.

176. Chaitman BR, Pepine CJ, Parker JO, et al: Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial, JAMA 291:309–316, 2004.

177. Isner JM, Asahara T: Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization, J Clin Invest 103:1231–1236, 1999.

178. Vincent KA, Shyu KG, Luo Y, et al: Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1alpha/VP16 hybrid transcription factor, Circulation 102:2255–2261, 2000.

179. Takeshita S, Zheng LP, Brogi E, et al: Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model, J Clin Invest 93:662–670, 1994.

180. Yang HT, Deschenes MR, Ogilvie RW, et al: Basic fibroblast growth factor increases collateral blood flow in rats with femoral arterial ligation, Circ Res 79:62–69, 1996.

181. Tsurumi Y, Takeshita S, Chen D, et al: Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion, Circulation 94:3281–3290, 1996.

182. Isner JM, Baumgartner I, Rauh G, et al: Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results, J Vasc Surg 28:964–973, 1998 discussion 973–965.

183. Baumgartner I, Pieczek A, Manor O, et al: Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia, Circulation 97:1114–1123, 1998.

184. Rajagopalan S, Mohler ER 3rd, Lederman RJ, et al: Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, doubleblind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication, Circulation 108:1933–1938, 2003.

185. Lederman RJ, Mendelsohn FO, Anderson RD, et al: Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial, Lancet 359:2053–2058, 2002.

186. Comerota AJ, Throm RC, Miller KA, et al: Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial, J Vasc Surg 35:930–936, 2002.

187. Nikol S, Baumgartner I, Van Belle E, et al: Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia, Mol Ther 16:972–978, 2008.

188. Belch J, Hiatt WR, Baumgartner I, et al: Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia, Lancet 377:1929–1937, 2011.

189. Powell RJ, Simons M, Mendelsohn FO, et al: Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia, Circulation 118:58–65, 2008.

190. Wang GL, Jiang BH, Rue EA, et al: Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension, Proc Natl Acad Sci U S A 92:5510–5514, 1995.

191. Guillemin K , Krasnow MA: The hypoxic response: huffing and HIFing, Cell 89:9–12, 1997.

192. Wenger RH, Gassmann M: Oxygen(es) and the hypoxia-inducible factor-1, Biol Chem 378:609–616, 1997.

193. Rajagopalan S, Olin J, Deitcher S, et al: Use of a constitutively active hypoxia-inducible factor-1alpha transgene as a therapeutic strategy in no-option critical limb ischemia patients: phase I dose-escalation experience, Circulation 115:1234–1243, 2007.

194. Creager MA, Olin JW, Belch JJ, et al: Effect of hypoxia-inducible factor-1{alpha} gene therapy on walking performance in patients with intermittent claudication, Circulation 124:1765–1773, 2011.

195. Kalka C, Masuda H, Takahashi T, et al: Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization, Proc Natl Acad Sci U S A 97:3422–3427,

2000.

196. Kamihata H, Matsubara H, Nishiue T, et al: Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines, Circulation 104:1046–1052, 2001.

197. Shintani S, Murohara T, Ikeda H, et al: Augmentation of postnatal neovascularization with autologous bone marrow transplantation, Circulation 103:897–903, 2001.

198. Tateishi-Yuyama E, Matsubara H, Murohara T, et al: Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial, Lancet 360:427–435, 2002.

199. Forbes TL: Rationale and design of the JUVENTAS trial for repeated intra-arterial infusion of autologous bone marrow-derived mononuclear cells in patients with critical limb ischemia. Commentary, J Vasc Surg 51:1568, 2010.

200. Walter DH, Krankenberg H, Balzer JO, et al: Intraarterial administration of bone marrow mononuclear cells in patients with critical limb ischemia: a randomized-start, placebocontrolled pilot trial (PROVASA), Circ Cardiovasc Interv 4:26–37, 2011.

201. Wester T, Jorgensen JJ, Stranden E, et al: Treatment with autologous bone marrow mononuclear cells in patients with critical lower limb ischaemia. A pilot study, Scand J Surg 97:56–62, 2008.

202. Lara-Hernandez R, Lozano-Vilardell P, Blanes P, et al: Safety and efficacy of therapeutic angiogenesis as a novel treatment in patients with critical limb ischemia, Ann Vasc Surg 24:287–294, 2010.

203. Lu D, Chen B, Liang Z, et al: Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double-blind, randomized, controlled trial, Diabetes Res Clin Pract 92: 26–36, 2011.

204. Perin EC, Silva G, Gahremanpour A, et al: A randomized, controlled study of autologous therapy with bone marrow-derived aldehyde dehydrogenase bright cells in patients with critical limb ischemia, Catheter Cardiovasc Interv 78:1060–1067, 2011.

205. Powell RJ, Comerota AJ, Berceli SA, et al: Interim analysis results from the RESTORE-CLI, a randomized, double-blind multicenter phase II trial comparing expanded autologous bone marrow-derived tissue repair cells and placebo in patients with critical limb ischemia, J Vasc Surg 54:1032–1041, 2011.

206. Sprengers RW, Moll FL, Teraa M, et al: Rationale and design of the JUVENTAS trial for repeated intra-arterial infusion of autologous bone marrow-derived mononuclear cells in patients with critical limb ischemia, J Vasc Surg 51:1564–1568, 2010.

207. Mohler ER 3rd, Hiatt WR, Creager MA: Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease, Circulation 108:1481–1486,

2003.

208. Aronow WS, Nayak D, Woodworth S, et al: Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment, Am J Cardiol 92:711–712, 2003.

209. Mondillo S, Ballo P, Barbati R, et al: Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease, Am J Med 114:359–364, 2003.

210. Hiatt WR, Hirsch AT, Creager MA, et al: Effect of niacin ER/lovastatin on claudication symptoms in patients with peripheral artery disease, Vasc Med 15:171–179, 2010.

211. Brown BG, Zhao XQ, Sacco DE, et al: Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease, Circulation 87:1781–1791, 1993.

212. Liao JK, Bettmann MA, Sandor T, et al: Differential impairment of vasodilator responsiveness of peripheral resistance and conduit vessels in humans with atherosclerosis, Circ Res 68:1027–1034, 1991.

213. Anderson TJ, Meredith IT, Yeung AC, et al: The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion, N Engl J Med 332:488–493, 1995.

214. Treasure CB, Klein JL, Weintraub WS, et al: Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease, N Engl J Med 332:481–487, 1995.

215. Van Belle E, Rivard A, Chen D, et al: Hypercholesterolemia attenuates angiogenesis but does not preclude augmentation by angiogenic cytokines, Circulation 96:2667–2674, 1997.

216. Vasa M, Fichtlscherer S, Adler K, et al: Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease, Circulation 103:2885–2890,

2001.

217. West AM, Anderson JD, Epstein FH, et al: Low-density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease, J Am Coll Cardiol 58:1068–1076, 2011.

218. Norgren L, Jawien A, Matyas L, et al: Sarpogrelate, a 5-hT2A receptor antagonist in intermittent claudication. A phase II European study, Vasc Med 11:75–83, 2006.

219. Hiatt WR, Hirsch AT, Cooke JP, et al: Randomized trial of AT-1015 for treatment of intermittent claudication. A novel 5-hydroxytryptamine antagonist with no evidence of efficacy, Vasc Med 9:18–25, 2004.

220. Jaff MR, Dale RA, Creager MA, et al: Anti-chlamydial antibiotic therapy for symptom improvement in peripheral artery disease: prospective evaluation of rifalazil effect on vascular symptoms of intermittent claudication and other endpoints in Chlamydia pneumoniae seropositive patients (PROVIDENCE-1), Circulation 119:452–458, 2009.

221. Gornik HL, Creager MA: Arginine and endothelial and vascular health, J Nutr 134:2880S–2887S, 2004; discussion 2895 S.

222. Maxwell AJ, Schauble E, Bernstein D, et al: Limb blood flow during exercise is dependent on nitric oxide, Circulation 98:369–374, 1998.

223. Duffy SJ, New G, Tran BT, et al: Relative contribution of vasodilator prostanoids and NO to metabolic vasodilation in the human forearm, Am J Physiol 276:H663–H670, 1999.

224. Gordon MB, Jain R, Beckman JA, et al: The contribution of nitric oxide to exercise hyperemia in the human forearm, Vasc Med 7:163–168, 2002.

225. Boger RH, Bode-Boger SM, Thiele W, et al: Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease, J Am Coll Cardiol 32:1336–1344, 1998.

226. Maxwell AJ, Anderson BE, Cooke JP: Nutritional therapy for peripheral arterial disease: a double-blind, placebo-controlled, randomized trial of HeartBar, Vasc Med 5:11–19, 2000.

227. Oka RK, Szuba A, Giacomini JC, et al: A pilot study of L-arginine supplementation on functional capacity in peripheral arterial disease, Vasc Med 10:265–274, 2005.

228. Wilson AM, Harada R, Nair N, et al: L-arginine supplementation in peripheral arterial disease: no benefit and possible harm, Circulation 116:188–195, 2007.

229. Kleijnen J, Mackerras D: Vitamin E for intermittent claudication, Cochrane Database Syst Rev 2000 CD000987.

230. Ernst E: The risk-benefit profile of commonly used herbal therapies: Ginkgo, St. John's wort, ginseng, echinacea, saw palmetto, and kava, Ann Intern Med 136:42–53, 2002.

231. Pittler MH, Ernst E: Ginkgo biloba extract for the treatment of intermittent claudication: a meta-analysis of randomized trials, Am J Med 108:276–281, 2000.

232. Peters H, Kieser M, Holscher U: Demonstration of the efficacy of ginkgo biloba special extract EGb 761 on intermittent claudication–a placebo-controlled, double-blind multicenter trial, Vasa 27:106–110, 1998.

233. De Smet PA: Herbal remedies, N Engl J Med 347:2046–2056, 2002.

234. Lamas GA, Ackermann A: Clinical evaluation of chelation therapy: is there any wheat amidst the chaff? Am Heart J 140:4–5, 2000.

235. Evans DA, Tariq M, Sujata B, et al: The effects of magnesium sulphate and EDTA in the hypercholesterolaemic rabbit, Diabetes Obes Metab 3:417–422, 2001.

236. Anderson TJ, Hubacek J, Wyse DG, et al: Effect of chelation therapy on endothelial function in patients with coronary artery disease: PATCH substudy, J Am Coll Cardiol 41:420–425, 2003.

237. Sloth-Nielsen J, Guldager B, Mouritzen C, et al: Arteriographic findings in EDTA chelation therapy on peripheral arteriosclerosis, Am J Surg 162:122–125, 1991.

238. Villarruz MV, Dans A, Tan F: Chelation therapy for atherosclerotic cardiovascular disease, Cochrane Database Syst Rev 2002 CD002785.

239. Ernst E: Chelation therapy for peripheral arterial occlusive disease: a systematic review, Circulation 96:1031–1033, 1997.

CHAPTER

20 Endovascular Treatment of

Peripheral Artery Disease

Christopher J. White

The concept of nonsurgical catheter-based peripheral vascular revascularization was first described by Charles Dotter advanced with the development of balloon dilation catheters by Andreas Gruentzig.2 Catheter-based revascularization has largely replaced conventional open surgery as the treatment of first choice in selected patients treated for lower-extremity ischemia.

No single specialty program (cardiology, radiology, or surgery) offered training that satisfied the entire skill set needed to perform peripheral endovascular intervention ( this unmet need for a trained cadre of clinicians to care for patients with peripheral artery disease (PAD) prompted the development of a core cardiology training symposium (COCATS-11) to codify the necessary cardiology fellowship training.

Table 20-1). Recognition of

and further

Patient and Lesion Selection Criteria

Indications

ANATOMICAL AND FUNCTIONAL CRITERIA

Patient selection for catheter-based vascular intervention depends upon both anatomical and functional criteria ( Anatomical lesion criteria include ability to gain vascular access, a reasonable likelihood of crossing the lesion with a guidewire, and the expectation that a therapeutic catheter can be advanced across the target lesion ( out) stenting, or use of a stent for a failed balloon dilation attempt (in contrast to “primary” stenting, in which stents are placed with or without balloon predilation), has become the standard of practice for shorter, more discrete lesions. Longer lesions and occlusions are better treated with primary stent placement.

Availability of endovascular stents (balloon expandable and selfexpanding) has significantly extended the anatomical subset of patients who may be considered candidates for peripheral vascular intervention, particularly for longer stenotic lesions and occlusions. The rate-limiting step for nonsurgical revascularization of the aortoiliac vessels is the ability to pass a guidewire across the lesion. Regardless of the balloon dilation result, the option of stent placement offers a reliable and reproducible method to recanalize these large vessels.

Vascular access site complications following catheter-based procedures often can be treated with percutaneous therapy (

Fig. 20-2). Patients with hypotension and a high suspicion of

bleeding after common femoral artery (CFA) access require urgent diagnostic angiography from the contralateral femoral artery to determine the bleeding site. Rapid identification of the bleeding site may provide an opportunity for lifesaving hemostasis with balloon tamponade.

Functional criteria to select patients for peripheral endovascular revascularization typically include lifestyle- or vocational-limiting symptoms of claudication, critical limb ischemia (CLI; rest pain, nonhealing ulcers, or gangrene), or acute limb ischemia. Asymptomatic patients with anatomically suitable iliac artery lesions may be considered candidates for peripheral vascular intervention to facilitate vascular access, such as for intraaortic counterpulsation balloon placement or for vascular access to perform coronary intervention.

Patients with lifestyle-limiting symptoms of classical claudication or atypical claudication should first have an attempt at pharmacological therapy with cilostazol and supervised exercise training before endovascular intervention is attempted. If exercise training and pharmacotherapy are not

Fig. 20-1). A strategy of “provisional” (bail-

Table 20-2) .

3,5–8

effective, if patients are intolerant of cilostazol or cannot be treated with the drug because of heart failure (black box warning), or if a supervised exercise program is unavailable, an attempt at endovascular intervention is appropriate. In general, patients with claudication progress to limb loss at a rate of well under 5% per year, so endovascular revascularization is reserved for those patients with favorable anatomy who either fail conservative therapy and have lifestyle-limiting symptoms or have vocational-limiting symptoms. Therapeutic goals for claudicants are symptom relief, increased walking distance, and improved functionality and quality of life. For this reason, durability of the procedure becomes important; recurrent ischemic symptoms require repeated procedures.

Patients with CLI or limb-threatening ischemia (gangrene, nonhealing ulcer, or rest pain) are candidates for urgent revascularization. When considering a patient with CLI for revascularization, it is important to remember that multilevel disease (iliac, femoral, and tibial) is likely to be present and that simply improving “inflow” without addressing the more distal vascular lesions or runoff vessels may fail to solve the clinical problem. Patients with CLI (rest pain, nonhealing ulcers, or gangrene) typically have more extensive disease than claudicants and require urgent revascularization to prevent tissue loss

Prognosis for patients presenting with CLI is poor. with tobacco abuse and/or diabetes are 10 times more likely to require amputation. Patients with CLI tend to be older, with almost 50% of patients older than 80 years undergoing amputations. Within 3 months of presentation, 12% will require an amputation, and 9% will die; 1-year mortality rate is 22%. Anatomy suitable for endovascular therapy is often present in one or more below-knee vessels. Therapy should be designed to restore pulsatile straight-line flow to the distal part of the limb, with as low a procedural morbidity as possible. The guiding principle is that less blood flow is required to maintain tissue integrity than to heal a wound, so restenosis does not usually result in recurrent CLI unless there has been repeated injury to the limb. Therefore, the emphasis is less on long-term vessel patency and more on amputation-free survival.

The Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial was a multicenter randomized trial comparing an initial strategy of balloon angioplasty to open surgery in 452 patients with CLI.13 The primary outcome was time to amputation or death (amputation-free survival). After 6 months, the two treatment strategies did not differ significantly in amputation-free survival. There was no difference between the groups for qualityof-life outcomes, but for the first year of follow-up, costs associated with a surgery-first strategy were higher than for angioplasty. For this reason, the authors concluded that a percutaneous-first strategy was the treatment of choice in patients who are candidates for either surgery or endovascular intervention.

3,11

(see Table 20-2).

Contraindications

Relative contraindications to catheter-based peripheral vascular intervention include (1) lesions likely to generate atheroemboli and (2) lesions that are not dilatable. Other relative contraindications include any other instances in which risks of the procedure seem to outweigh potential benefits. For example, the risk of contrast-induced nephropathy in a patient with severe renal impairment must be weighed against expected functional improvement.

Those

259

260

Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/

TABLE 20-1

SKILL ELEMENT DESCRIPTION

Cognitive

Technical Competence in both diagnostic angiography

Clinical Ability to manage inpatients, interpret laboratory

Required Skill Elements for Optimal

Peripheral Vascular Intervention

Extensive knowledge of vascular disease, including

natural history, pathophysiology, diagnostic methods, and treatment alternatives

and interventional techniques, such as use and selection of balloons, guidewires, stents, and emboli protection devices

tests, obtain informed consent, assess risk/benefit ratio, and admitting privileges

Technical and Procedural Considerations

Prior to performing lower-extremity endovascular intervention, it is necessary to objectively determine the patient's functional status. A history, physical examination, and appropriate noninvasive testing should be obtained prior to planning peripheral endovascular revascularization. If the patient is ambulatory, a rest and exercise ankle-brachial index (ABI) should be measured, and pulse volume recordings (PVR) should be performed. Other noninvasive modalities, such as vascular ultrasound, or alternative imaging modalities, such as magnetic resonance angiography (MRA) or computed tomographic angiography (CTA), may be helpful to resolve conflicting data and are used at the discretion of the physician (

Fig. 20-3). When planning lower-extremity revascular-

ization, status of the inflow and outflow vessels relative to the target lesion must be visualized angiographically. This is usually done with invasive diagnostic angiography, but in selected patients, MRA or CTA may be very useful.

Preprocedure

GENERAL MEASURES

Prior to performing peripheral endovascular intervention, the patient should have a complete cardiovascular evaluation, with specific attention directed to the status of atherosclerotic risk factors. Atherosclerosis is a systemic disease, and appropriate riskfactor modification (tobacco-cessation counseling, treatment of lipids to target values), screening tests for cardiovascular diseases, and optimization of medical therapy should be performed.

PREMEDICATION

The only premedication requirement for peripheral endovascular intervention is aspirin therapy (81-325 mg daily). Use of other antiplatelet agents is optional, since there is no evidence that their use improves procedural success or decreases complications. If the patient is intolerant to aspirin, a thienopyridine drug would be appropriate. There is no evidence supporting use of dual antiplatelet therapy after peripheral endovascular intervention or following peripheral vascular stent placement.

TABLE 20-2 Classification of Peripheral Arterial Disease: Fontaine's Stages and Rutherford's Categories

Fontaine Rutherford

STAGE CLINICAL GRADE CATEGORY CLINICAL

I Asymptomatic 0 0 Asymptomatic

IIa Mild claudication I 1 Mild claudication

IIb Moderate to severe claudication I

III Rest pain II 4 Rest pain

IV Ulceration or gangrene III

From Norgren L, Hiatt WR, Dormandy JA, et al: Inter-Society Consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 45 Suppl S:S5–S67, 200711.

2 3

5 6

Moderate claudication Severe claudication

Minor tissue loss Ulceration or gangrene

FIGURE 201 A, Tight stenosis of infrarenal aorta amenable to angioplasty. B, Final postangioplasty result.

ABC

FIGURE 202 Access site complication with bleeding (A) successfully tamponaded with balloon inflation (B), and final angiogram showing hemostasis.

receptor antagonists, low-molecular-weight heparins, or antithrombins improve procedural efficacy or safety for peripheral vascular intervention.

261

CH 20

EndovAsCulAR TREATmEnT of PERiPHERAl ARTERy disEAsE

FIGURE 203 Computed tomographic angiogram (CTA) of lower- extremity vasculature. There is occlusion of arterial segments of the right

femoral, popliteal, and tibial segments.

Procedure

ANTICOAGULATION

There is no standard for anticoagulation therapy, except to state that intravenous unfractionated heparin (UFH), in a dose up to 5000 International Units, is commonly used to achieve an activated clotting time (ACT) of 250 to 300 seconds. At present, there is no evidence that use of glycoprotein (GP)-IIb/IIIa platelet

VASCULAR ACCESS

The first step to ensure a successful procedure is to plan appropriate vascular access. The majority of peripheral endovascular intervention can be performed from multiple arterial access sites (i.e., radial, brachial, femoral, or popliteal arteries). However, cases occasionally require a specific access to achieve a successful result. Consequently, familiarity with a variety of vascular access sites and techniques is one of the most important components of the basic skill set. Ability to gain both retrograde and antegrade common femoral access is a required skill for the interventionalist. An infrapopliteal target lesion may be best approached with antegrade femoral access, whereas a proximal superficial femoral artery lesion may require a contralateral retrograde femoral approach. Occasionally, bilateral retrograde femoral artery access is desirable—for example, when treating a common iliac bifurcation lesion.

Equipment Choices

GUIDEWIRES

Trade-offs include smaller catheters with crossing lower profiles, smaller sheath sizes, and increased flexibility for the smallest 0.014-inch systems, which must be balanced against the increased support and pushability of the larger-profile

0.035-inch systems. It is most common that 0.014-inch systems are used for below-knee intervention where the vessels are smaller, compared to the usual 0.035-inch systems used for the larger balloons and stents placed in the iliac vessels. It is recommended that the interventional laboratory be stocked with several redundant lines of equipment to allow for flexibility in the approach to difficult or complex lesions. In general, the lowest profile system within the smallest vascular access sheath should be used.

Use of coated “glidewires” should be carefully restricted to instances when their unique properties are necessary because these wires are more difficult to control than conventional guidewires and are prone to vascular perforation. Their lack of a “transition point” makes them ideal for negotiating abrupt angles and

262

Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/

crossing occlusions. Ideally, once they have crossed the occlusion, it is wise to exchange this potentially dangerous wire for a safer and more controllable wire.

BALLOON CATHETERS

A wide variety of monorail and over-the-wire balloon catheters are

available that are suitable for dilating lower-extremity lesions. They

come in a variety of diameters, with balloon lengths up to 15 cm. A pressure manometer is recommended to monitor balloon inflation pressure. Although no optimal inflation pressure or duration has been determined, it is generally recommended that the balloon be inflated with adequate pressure to ensure full expansion of the lesion.

STENTS

The two categories of stents are balloon expandable and selfexpanding. Both types may be covered with material. Balloon expandable stents are intended for use within the axial skeleton to protect them from external compression. This generally limits their use to the iliac arteries, but coronary balloon expandable stents are used to salvage failed angioplasty results in below-knee

14,15

vessels.

Balloon expandable stents can be deployed with more precision than self-expanding stents, although there is some shortening associated with their expansion. Self-expanding stents resist permanent deformation and are elastic. Their flexible nature allows them to delivered in longer lengths, and they will fit themselves to a tapering artery. Self-expanding stents may be made of nitinol or a stainless steel alloy. At this time, there is no evidence that either material is associated with any safety or efficacy advantage.

ADJUNCTIVE DEVICES

Other adjunctive devices, such as laser catheters, atherectomy catheters (rotational and directional), brachytherapy catheters, cryotherapy balloons, and cutting balloons have been developed, tested, and aggressively marketed. With the possible exception

16,17

of the brachytherapy devices, there is no comparative evidence that these adjunctive devices bring any added value, efficacy, or increased safety over balloons and stents when treating lower extremities.

Clinical Outcomes

Aortoiliac Vessels

The current best practice, in experienced hands, for aorto-iliac lesions favors an endovascular strategy ( dation is based upon the morbidity and mortality associated with major vascular surgery in patients with significant comorbidity, and the excellent outcomes available with current endovascular techniques. In a large single-center registry of 505 iliac stent procedures, the technical success rate was 98%, 8-year primary stent patency rate was 74%, and secondary patency rate was 84%. 10-year iliac stent patency study, there was no effect of age, diabetes, tobacco smoking, or hypertension on patency. artery (CIA) lesions had greater long-term patency than external iliac artery (EIA) lesions. Outcomes from another series of 89 consecutive patients with symptomatic occluded iliac arteries demonstrated a 92% success rate for endovascular treatment. severity and complexity of lesions did not significantly alter iliac artery patency rates.

An observational study compared nonrandomized results of iliac artery stenting with surgery in patients with moderately complex lesions.

There was no difference regarding limb salvage or patient survival out to 5 years, but vessel patency was reduced in limbs treated with stents compared to surgery. A nonrandomized retrospective comparison of endovascular intervention compared to open surgery for complex aortoiliac occlusive lesions found a shorter hospital stay, fewer postprocedural complications, and lower primary patency rates but equivalent secondary patency rates for the endovascular arm.

There is debate regarding the most efficacious method of endovascular therapy between “provisional stent placement,” which is selective use of stents only when balloon dilation has failed or is

Fig. 20-4). This recommen-

In a

Common iliac

Increasing

Aorta

Common

iliac

FIGURE 204 Left, Baseline angiogram of right common iliac stenosis. Right, Angiogram after angioplasty and self-expanding stent (arrows).

<<< < Предыдущая 14 15 16 17 18 19 20 21 22 23 24 2526 / 5026 27 28 29 30 31 32 33 34 35 36 37 38 > Следующая >>>

Соседние файлы в папке Библиотека им академика М.И. Перельмана

#
29.08.202684 Мб0Книга_3602_Библиотеки_им_академика_М_И_Перельмана.pdf
#
29.08.202684 Мб0Книга_3603_Библиотеки_им_академика_М_И_Перельмана.pdf
#
29.08.202683 Мб0Книга_3604_Библиотеки_им_академика_М_И_Перельмана.pdf
#
29.08.202683 Мб0Книга_3605_Библиотеки_им_академика_М_И_Перельмана.pdf
#
29.08.202683 Мб0Книга_3607_Библиотеки_им_академика_М_И_Перельмана.pdf
#
29.08.202683 Мб0Книга_3608_Библиотеки_им_академика_М_И_Перельмана.pdf
#
29.08.202681 Мб0Книга_3609_Библиотеки_им_академика_М_И_Перельмана.pdf
#
30.08.202679 Мб0Книга_3610_Библиотеки_им_академика_М_И_Перельмана.pdf
#
30.08.202676 Мб0Книга_3611_Библиотеки_им_академика_М_И_Перельмана.pdf
#
30.08.202674 Мб0Книга_3612_Библиотеки_им_академика_М_И_Перельмана.pdf
#
30.08.202674 Мб0Книга_3613_Библиотеки_им_академика_М_И_Перельмана.pdf